CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 180 enrolled
Drug / intervention
Woebot Substance Use Disorderother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04460027
NCT04460027Phase 1Completed
CompareCT.gov

Woebot for Substance Use Disorders During COVID-19

Woebot Health·interventional·Posted Jul 7, 2020·Updated Dec 21, 2022

In Brief

A Phase 1 clinical trial evaluating Woebot Substance Use Disorder for Substance Use Disorders and Alcohol Use Disorder. Completed, enrolled 180 participants across 1 site.

Detailed Summary

The purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic. This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to a wait list control condition, and explore between group differences on quality of life indices as well as retention and engagement during COVID-19.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubstance Use Disorders, Alcohol Use Disorder
CountriesUnited States
CollaboratorsStanford University, National Institute on Drug Abuse (NIDA)

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedJul 7, 2020
Enrollment StartJun 22, 2020
Primary CompletionNov 30, 2020
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.0 years ago

Interventions

Woebot Substance Use Disorderother

Woebot Substance Use Disorder is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.